Brief: Crossject H1 net loss widens to 3.4 million euros

Crossject SA

21/09/2017 17:25

Sept 21 (Reuters) - CROSSJECT SA  ALCJ.PA : 
    * H1 NET LOSS EUR 3.4 MILLION VERSUS LOSS OF EUR 2.8 
MILLION YEAR AGO 
    * H1 OPERATING LOSS EUR  4.3 MILLION VERSUS LOSS OF EUR 
2.8 MILLION YEAR AGO 
    * CASH POSITION AT JUNE 30 EUR 6.1 MILLION 
    * TO BE ABLE TO RELY ON ADDITIONAL CASH ESTIMATED AT  5.9 
MILLION UNTIL DEC., 31 2018 
    * CLINICAL STUDIES FOR ZENEO SUMATRIPTAN, ZENEO ADRENALINE 
AND ZENEO MIDAZOLAM SHOULD BE COMPLETED IN 2018 
 
Source text for Eikon:  ID:nGNE70MCn7  
Further company coverage:  ALCJ.PA  
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))